Form 4: Ionis Director Sells 16,800 Shares Under 10b5-1 Plan

Ionis Pharmaceuticals Director Joseph H. Wender sold 16,800 shares of common stock for approximately $1.1 million on October 1, 2025, under a pre-arranged trading plan.

Summary

• Joseph H. Wender, a Director of Ionis Pharmaceuticals Inc. (IONS), reported the sale of 16,800 shares of common stock.
• The transaction occurred on October 1, 2025.
• The shares were sold at a weighted average price of $65.4991 per share, with individual transaction prices ranging from $65.02 to $65.86.
• The total value of the shares sold amounts to approximately $1,099,984.88.
• This sale was executed pursuant to a Rule 10b5-1 Trading Plan, which was adopted by Mr. Wender on December 26, 2024.
• Following this transaction, Mr. Wender beneficially owns 92,035 shares indirectly through a Trust.

Sentiment

Score: 5

Explanation: The filing reports a routine insider stock sale executed under a pre-arranged 10b5-1 trading plan, which typically does not indicate a change in management's outlook or company fundamentals, thus maintaining a neutral sentiment.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing reports a routine insider transaction and does not provide information directly related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: A routine insider sale under a 10b5-1 plan is generally not considered a significant indicator of future company performance and is unlikely to have a material impact on shareholder sentiment or the stock price.

Key Dates

Recommendation

A single, pre-scheduled insider sale by a director, executed under a Rule 10b5-1 plan, is generally considered a routine event and does not typically warrant a change in investment recommendation for the company's stock. It does not reflect new information about the company's performance or future prospects, thus a 'hold' recommendation is appropriate.

Keywords

Ionis Pharmaceuticals, IONS, Joseph H. Wender, Insider Trading, Form 4, Stock Sale, Director, 10b5-1 Plan